GPX4 and neoplasm: Luo et al. (2022) designed a GPX4 degrader, dGPX4, that degrades GPX4 in tumor cells via the proteasome pathway, achieving an efficiency five times greater than that of inducing ferroptosis with ML162, a GPX4 inhibitor.